Change of Auditor

About this update from Thalia Therapeutics Plc

23 August 2024 N4 Pharma plc ("N4 Pharma" or the "Company")   Change of Auditor   N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments, gene therapy and vaccines, announces that it has appointed Gravita II LLP as the Company's auditor.   In accordance with section 519 of the Companies Act 2006, the previous auditor, Saffery LLP, has deposited with the Company a statement confirming that there are no matters to be brought to the attention of the Company's members or creditors.   For more information please contact:   N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director   Engage with us directly at N4 Pharma Investor Hub   To hear more, visit   Via N4 Pharma Investor Hub     Sign up at investors.n4pharma.com     SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) Tel: +44(0)20 3470 0470 Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker James Pope Tel: +44(0)20 3657 0050     About N4 Pharma N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec® and Liptide, a unique peptide/lipid delivery system via its subsidiary Nanogenics.   N4 Pharma's business model is to partner with companies developing products in these fields to use Nuvec® or Liptide® as the delivery vehicle for these products. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.   For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com .

View stock analysis, news, and events for Thalia Therapeutics Plc